Joseph Walter Strohbach,David Christopher Limburg,John Paul Mathias,Atli Thorarensen,Rajiah Aldrin Denny,Christoph Wolfgang Zapf,Daniel Elbaum,Lori Krim Gavrin,Ivan Viktorovich Efremov
申请号：
US16578277
公开号：
US20200017512A1
申请日:
2019.09.20
申请国别(地区):
US
年份:
2020
代理人:
摘要：
The present invention relates to methods of using compounds of Formula I,wherein R1a, R1b, R2, R3, R4, W, Y, and Z are as described herein, and pharmaceutically acceptable salts thereof. The compounds are potentiators of Cystic Fibrosis Transmembrane conductance Regulator (CFTR). The invention also discloses pharmaceutical compositions comprising the compound, optionally in combination with additional therapeutic agents, and methods of potentiating, in mammals, including humans, CFTR by administration of the compounds. These compounds are useful for the treatment of cystic fibrosis (CF), asthma, bronchiectasis, chronic obstructive pulmonary disease (COPD), constipation, Diabetes mellitus, dry eye disease, pancreatitis, rhinosinusitis, Sjögren's Syndrome, and other CFTR associated disorders.
